Skip to main content
. 2021 Oct 9;11(10):2923. doi: 10.3390/ani11102923

Table 2.

Correlation between patient signalment and serum eAGR2 concentration.

Characteristics Case Number eAGR2 (µg/mL) 1 p-Value
Age (years) 2
 BMT
  <10 12 4.34 ± 1.934 0.831
  ≥10 9 4.54 ± 1.879 -
 MMT
  <10 33 5.58 ± 2.788 0.419
  ≥10 48 6.23 ± 2.957 -
 Total
  <10 45 4.91 ± 2.625 0.199
  ≥10 57 5.32 ± 2.869 -
Body weight (kg) 2
  <6.7 51 4.91 ± 2.265 0.103
  ≥6.7 51 5.43 ± 3.162 -
Neuter status 2
  No 62 5.11 ± 3.021 0.739
  Yes 40 5.24 ± 2.370 -
MMT subtype 3
Simple carcinoma 45 6.32 ± 2.878 0.168
Complex carcinoma 26 5.86 ± 3.072 -
Multiple MMTs 10 4.66 ± 2.224 -
Metastasis 2
  No 85 5.20 ± 2.324 0.002 **
  Yes 17 7.93 ± 3.682 -
Stage 3
  I/II 48 4.76 ± 2.459 0.0007 ***
  III/IV 24 5.29 ± 2.734 -
  V 9 8.81 ± 2.762 -

1 Data are shown as mean ± SD. p-value < 0.05 is considered statistically significant; ** p < 0.01; *** p < 0.001. 2 Comparison between groups was determined by Mann–Whitney U test. 3 Comparison between groups was determined by Kruskal–Wallis H test.